从研发到出海，北京15条举措打造医疗器械产业高地

Core Viewpoint - The Beijing Municipal Bureau of Economy and Information Technology, along with five other departments, has issued measures to promote the high-quality development of the medical device industry, aiming to enhance innovation and practical application from 2025 to 2028 [1] Group 1: Full-Chain Support for Medical Device Enterprises - The measures address key challenges faced by medical device companies, such as difficulties in R&D, slow market entry, and promotion issues, by establishing a comprehensive support system [3] - The measures encourage collaboration between enterprises, research institutions, and medical organizations to form innovative joint entities, facilitating the transformation of medical technology innovations [3] - Approval times for urgently needed medical devices have been significantly reduced, with non-source medical devices and diagnostic reagents now averaging 60 working days for inspection, and active medical devices averaging 90 working days [3] Group 2: Ecosystem Development and Industry Resilience - The measures emphasize the construction of high-quality industrial spaces for the medical device sector and encourage joint innovation to tackle challenges in key components and raw materials [4] - Financial support of up to 30% of project costs, capped at 30 million yuan, is available for collaborative efforts to enhance the resilience of the industry chain [4] Group 3: Digitalization and Open Collaboration - Digital empowerment is highlighted as a crucial engine for upgrading the medical device industry, with initiatives to build high-quality data sets and support the development of industry-specific AI models [5] - The measures promote the integration of AI in medical services and support the digital transformation of production, inspection, and management processes within medical device companies [5] - To enhance international competitiveness, the measures provide financial support for medical devices that gain approval from international regulatory bodies, with individual product support capped at 1 million yuan and annual support for each company not exceeding 3 million yuan [6]